tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Artivion announces presentations of clinical data from Nexus and AMD trials
PremiumThe FlyArtivion announces presentations of clinical data from Nexus and AMD trials
11d ago
Artivion: Strategic Growth, Market Expansion, and Long-Term Value Creation Drive Buy Rating
Premium
Ratings
Artivion: Strategic Growth, Market Expansion, and Long-Term Value Creation Drive Buy Rating
2M ago
Artivion Inc. Reports Robust Earnings Amid Growth Challenges
Premium
Company Announcements
Artivion Inc. Reports Robust Earnings Amid Growth Challenges
3M ago
Artivion price target raised to $51 from $50 at Canaccord
PremiumThe FlyArtivion price target raised to $51 from $50 at Canaccord
3M ago
Artivion price target raised to $53 from $47 at Citizens JMP
Premium
The Fly
Artivion price target raised to $53 from $47 at Citizens JMP
3M ago
Artivion’s Strong Q3 Performance and Growth Prospects Justify Buy Rating
Premium
Ratings
Artivion’s Strong Q3 Performance and Growth Prospects Justify Buy Rating
3M ago
AORT Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsAORT Upcoming Earnings Report: What to Expect?
3M ago
Artivion Inc. Advances Aortic Treatment with New Clinical Study
Premium
Company Announcements
Artivion Inc. Advances Aortic Treatment with New Clinical Study
4M ago
Artivion announces data from AMDS PERSEVERE and PROTECT trials
Premium
The Fly
Artivion announces data from AMDS PERSEVERE and PROTECT trials
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100